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The use of statistical methods is now firmly established in all
areas of clinical research, as is clearly demonstrated by even
a casual glance at the medical literature. In particular, the
integral importance of statistical methods in clinical cancer
research is widely recognised (Williams, 1992). Further, prob-
lems posed in such research have in their turn been the
stimulus for the development of new statistical methods.
Thus the investigation of possible environmental causes of
cancer, such as the possible link between smoking and lung
cancer, motivated the development ofmethods for the design
of epidemiological studies, particularly the case-control
study, and techniques for analysing the resulting data
(Cornfield, 1951; Mantel & Haenszel, 1959). The importance
of methods associated with randomised clinical trials in
leukaemia led to two seminal papers on the design and
analysis of studies of survival time, including a detailed
description of the logrank test, which were published in this
journal (Peto et al., 1976, 1977). These papers, together with
the paper by Cox (1972) describing the proportional hazards
multiple regression model for survival data, have had a huge
positive impact on the ability to analyse and interpret com-
plex medical data such as arise throughout the field of
cancer, and have been heavily cited in medical journals (Alt-
man, 1991; Andersen, 1991). It is significant in this context
that Sir David Cox recently won a prestigious award from
the American Cancer Association to acknowledge the impor-
tance of his innovation.
In parallel with the development of new statistical
methodology there has been the amazing increase in the
power and availability of computing facilities. This develop-
ment not only influences our ability to handle very large
quantities of data in an efficient and speedy manner, but it
also enables us to use complex statistical techniques, for
example the Cox model, which would not otherwise be possi-
ble. Further, suitable software is now easily accessible on
personal computers and so is within reach of most resear-
chers. However, this reliance on the computer for statistical
analysis leads to the dangers of using statistical techniques as
a 'black box' without adequate understanding of the underly-
ing principles, the restriction on their validity, or a proper
appreciation of their interpretation. The ready availability of
statistical software does not obviate the need to seek statis-
tical advice when analysing data.
In recent years there has been increasing realisation that
statistical methods have been misused in many publications
in the medical scientific literature (Altman, 1982, 1991;
Andersen, 1990). This misuse has led many journals, includ-
ing the British Medical Journal and Lancet, to include review
by statisticians as part of the editorial process. The British
Journal of Cancer is currently considering its own policy on
statistical refereeing. Statistical appraisal of submitted papers
serves not only to avoid the most obvious errors in presenta-
tion and analysis but also to examine critically aspects of
good design. Inappropriate analysis, poor presentation and
incorrect conclusions can readily be rectified. By contrast,
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deficiencies in study design usually cannot be overcome. For
example, with respect to clinical trials particular emphasis is
placed on the use of an acceptable method of randomisation
and having sufficient patient numbers recruited to achieve
reasonable statistical power. The statistical review process
can be aided by the use of check lists (Gardner et al., 1986)
and these also serve both as a useful guide at the critical
design stage of any study and also as a final check before
submission to the appropriate journal. Not all journals men-
tion statistical methods in their 'Guidelines to Authors',
although there is a paragraph in the 'Vancouver' guidelines
(International Committee of Medical Journal Editors 1988).
One key requirement is that authors should describe statis-
tical methods with enough detail to enable a knowledgeable
reader with access to the original data to verify the reported
results.' In other words, it is especially important to describe
methodology, including the study design and methods of
analysis, in some detail. The statistical component of the
Vancouver guidelines has been expanded by Bailar and
Mosteller (1988). Statistical guidelines have also been pub-
lished for cancer studies (Simon & Wittes, 1985) and for
medical papers in general (Altman et al., 1983). It is increas-
ingly likely that a paper submitted to a leading medical
journal will be refereed by a medical statistician.
The essence of all clinical research is to use observations
made on a sample of patients to make inferences about the
population of all such patients. The sample of patients with,
say, acute myeloid leukaemia acts as a proxy for all such
patients. It is important, therefore, that the study sample
should be representative of the population of interest other-
wise such extrapolation will mislead. In practice, samples of
patients are usually at least partly determined by practical
considerations, so it is essential to describe fully the patients'
demographic and clinical characteristics. In comparative
studies, including controlled trials and case-control studies, a
representative sample is perhaps less important, but it is
essential that the groups being compared are not system-
atically different. In controlled trials bias is eliminated by
randomisation; in other types of study the possibility of bias
needs to be carefully considered. While controlled trials allow
a direct interpretation of cause (treatment) and effect, non-
randomised studies are prone to many type of bias, so that
conclusions in general should be rather more cautious.
A particularly important change in emphasis in recent
years (Altman, 1991) has been the move from hypothesis
testing and slavish reporting of P values without estimates of
the size of, for example, differences between treatments being
reported, to stressing the value of confidence intervals (Gard-
ner & Altman, 1989). Most research is related to
quantification of effects or relationships, and this cannot be
done by P values. The minimalist use of 'NS' as the sole
description of an analysis is particularly undesirable. Not
only are the actual estimates (such as means or proportions)
much more valuable, but confidence intervals allow uncer-
tainty in these estimates to be quantified. A 95% confidence
interval may be intepreted as giving the range of true values
that the results are compatible with. Confidence intervals
have been adopted quite widely in general medical journals
(Altman, 1991) but seem to be used less often in specialist
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journals. Also, they appear to be used more widely by those
who report clinical trials, but are hardly used in reports of
laboratory based research, although they are equally app-
licable for both.
In recognition of both the importance of statistics and its
complexity the British Journal ofCancer is publishing a series
of guest editorials relating to the use of statistics in cancer
research, with the emphasis on clinical studies. The objectives
of this series are partly to stress the need for the appropriate
use of statistical methodology but more importantly to
debate some issues that are not always so immediately
understood or accepted. Thus topics addressed include
several relating to clinical trials - the use of interim analysis
and stopping rules, surrogate endpoints (such as disease free
survival or rise in biological markers), and the policy of
analysing data by intention-to-treat. Despite the statistical
advances already referred to the analysis of survival data still
causes difficulty, and so one editorial will examine some of
the problematic aspects. Aspects of design will also be
covered, in particular the important area of observer agree-
ment studies concerned with review of pathological sections
and radiographs, and the difficult issue of determining appro-
priate sample size. Other issues to be covered include meta-
analysis and the design and analysis of studies of prognostic
factors. Although the emphasis in this series is on clinical
studies, many broadly similar considerations apply to
laboratory studies, as again the results are taken as indicative
of what would happen more widely.
It is important to emphasise that statistics and statisticians
do not provide all the answers. The science of statistics is
young and is developing all the time, alongside and often
motivated by real problems, not least those posed by cancer
research. Some examples of the influence of cancer research
on statistical methodology were given earlier. Another is the
randomised consent design for controlled trials proposed by
Zelen (1979), although this controversial design has rarely
been used in cancer trials (Altman et al., 1993). A more
recent example is the methodology being developed to design
and analyse studies of quality of life, which is the subject of
another of the forthcoming editorials. We hope that this
series will stimulate discussion in this journal, a wider
understanding of the issues involved, help authors to design
their studies and analyse their data, and so ultimately benefit
the quality of research conducted in the field of cancer.
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